Versant Capital Management, Inc - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 105 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2019. The put-call ratio across all filers is 56.95 and the average weighting 0.3%.

Quarter-by-quarter ownership
Versant Capital Management, Inc ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q1 2021$5,000
+25.0%
2390.0%0.00%0.0%
Q4 2020$4,000
+33.3%
2390.0%0.00%
+100.0%
Q3 2020$3,000
-40.0%
2390.0%0.00%
-50.0%
Q2 2020$5,0000.0%2390.0%0.00%
-33.3%
Q1 2020$5,000
-16.7%
239
-5.2%
0.00%0.0%
Q4 2019$6,000
+20.0%
252
-18.2%
0.00%
+50.0%
Q3 2019$5,000308
+2980.0%
0.00%
Q1 2019$0100.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q1 2019
NameSharesValueWeighting ↓
Madison Avenue Partners, LP 7,012,226$60,515,5108.59%
Irenic Capital Management LP 2,760,948$23,826,9816.76%
Newtyn Management, LLC 1,841,560$15,892,6633.92%
Weiss Asset Management LP 7,457,060$64,354,4283.81%
Park West Asset Management LLC 1,983,251$17,115,4561.57%
Baupost Group 7,419,226$64,0281.23%
Oasis Management Co Ltd. 953,254$8,226,5820.36%
Chescapmanager LLC 287,333$2,479,6840.32%
GSA CAPITAL PARTNERS LLP 325,985$2,8130.24%
Virtus ETF Advisers LLC 29,232$252,2720.15%
View complete list of THERAVANCE BIOPHARMA INC shareholders